# 非注射胰岛素市场

> 非注射胰岛素市场研究报告按产品类型（胰岛素贴片、胰岛素吸入器、胰岛素笔、胰岛素凝胶）、按治疗领域（1型糖尿病、2型糖尿病、妊娠糖尿病）、按分销渠道（医院药房、零售药房、在线药房）、按最终用户（医院、居家护理、糖尿病诊所）和按地区（北美、欧洲、南美、亚太、中东和非洲） - 增长与行业预测2025至2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.67%
- **2024:** $ 8.5 Billion
- **2025:** $ 8.98 Billion
- **2035:** $ 15.59 Billion
- **Key Players:** Novo Nordisk (DK), Sanofi (FR), Boehringer Ingelheim (DE), Bristol-Myers Squibb (US), MannKind Corporation (US), Eli Lilly and Company (US), AstraZeneca (GB), Pfizer (US), Roche (CH)

**Report ID:** MRFR/HC/33136-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** November 11, 2026

**URL:** https://www.marketresearchfuture.com/reports/non-injectable-insulin-market-35002

---

## Market Summary

## **Non-injection Insulin Market Overview**

As per MRFR analysis, the Non Injectable Insulin Market Size was estimated at 8.50 (USD Billion) in 2024. The Non Injectable Insulin Market Industry is expected to grow from 8.98 (USD Billion) in 2025 to 14.75 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 5.67% during the forecast period (2025 - 2034).

### **Key Non-injection Insulin Market Trends Highlighted**

The Non-injection Insulin Market is witnessing significant growth driven by the increasing prevalence of diabetes and a rising demand for alternatives to traditional injection methods. Patients are increasingly seeking non-invasive options for insulin delivery that offer convenience and comfort.

The advancements in technology have enabled the development of inhalable insulin, insulin patches, and oral formulations, enhancing adherence to treatment plans among diabetic patients. Moreover, growing awareness about diabetes management and a shift towards preventive healthcare are key factors fueling market expansion.

There are ample opportunities to be explored in this market, particularly in expanding research for effective non-injection delivery systems.

Innovations in wearables and smart technology can also integrate with insulin delivery systems to promote more personalized and efficient diabetes management. Collaborations between pharmaceutical companies and technology firms can further drive product development, creating unique offerings that cater to the needs of patients.

Additionally, untapped geographical markets present a significant opportunity for growth as awareness and accessibility improve. Recent trends indicate a substantial shift towards patient-centric solutions that prioritize user experience. Non-injection insulin therapies are increasingly being viewed as part of comprehensive diabetes care strategies rather than standalone products.

The rise of telehealth services and remote patient monitoring has also affected how diabetic patients engage with their management plans.

The social stigma surrounding insulin use is fading as more patients openly discuss their choices, leading to greater acceptance of non-injection alternatives. These trends reflect an evolved landscape where non-injection insulin therapies could play a critical role in diabetes care in the foreseeable future.

****

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Non-injection Insulin Market Drivers**

### Rising Prevalence of Diabetes

The increasing prevalence of diabetes globally is a significant driver for the Non-injection Insulin Market. As the number of individuals diagnosed with diabetes continues to rise, there is a corresponding increase in demand for effective management solutions.

The growing awareness surrounding diabetes management and the benefits of using non-injection insulin forms are contributing to market growth. Non-injection insulin options, such as inhalable insulin, are becoming increasingly popular due to their ease of use, which can significantly enhance patient compliance.

Furthermore, the rising focus on self-management of diabetes and preventative healthcare is highlighting the necessity for non-invasive delivery mechanisms. Patients often seek alternatives to traditional injection methods because of the pain, inconvenience, and anxiety associated with needles.

This trend is particularly strong among younger patients and those who may experience a negative psychological response to injections, thus driving a quicker acceptance and integration of non-injection insulin into diabetes management plans.

Moreover, healthcare providers are recognizing the need for non-injection options as part of a broader strategy to enhance patient quality of life and manage chronic conditions more effectively. This has resulted in an increase in research and development activities focused on creating innovative non-injection insulin products, further bolstering the market landscape.

The impact of diabetes on overall health systems and economies cannot be understated, leading governments and organizations to advocate for advanced solutions that minimize complications and hospitalization risks associated with diabetes.

Consequently, as the population ages and lifestyle-related conditions continue to escalate, the Non-injection Insulin Market is projected to experience substantial growth, driven by the urgent need for efficient and patient-friendly treatment alternatives.

### Technological Advancements

Technological advancements in drug delivery systems are paving the way for innovative non-injection insulin products and significantly boosting the Non-injection Insulin Market.

As research and development efforts focus on improving the efficiency of insulin administration, new delivery methods, such as inhalable insulin and wearable devices, are emerging. These technologies not only offer patients more convenient and pain-free options, but they also enhance the accuracy of dosage delivery.

Enhanced formulations that ensure better absorption rates and prolonged effects are helping to secure the trust of both consumers and healthcare professionals. Moreover, these advancements are closely aligned with the increasing integration of digital health tools, which further expand the market reach of non-injection insulin products.

### Growing Emphasis on Patient-Centric Care

The shift toward patient-centric care models in healthcare is a strong driver for the Non-injection Insulin Market.

As healthcare systems prioritize personalized treatment and patient engagement, non-injection insulin options are being favored for their ability to improve patient experience and satisfaction. Healthcare providers are recognizing the importance of patients' preferences in treatment outcomes, and as such, the availability of non-invasive insulin delivery methods supports this paradigm shift.

This focus on patient-centric solutions not only enhancing compliance rates but is also encouraging more individuals to take an active role in their diabetes management.

## **Non-injection Insulin Market Segment Insights**

### **Non-injection Insulin Market Product Type Insights**

The Non-injection Insulin Market has shown promising growth and diversification, particularly within its Product Type segmentation, which includes Insulin Patches, Insulin Inhalers, Insulin Pens, and Insulin Gels.

In 2023, Insulin Pens dominated the market with a valuation of 3.0 USD billion, reflecting their widespread acceptance and convenience among diabetics, making them a significant option for patients seeking ease of administration.

Following closely, Insulin Inhalers reached a valuation of 2.03 USD billion, showcasing their role in providing an alternative to traditional insulin delivery methods and appealing particularly to those with a preference for non-injection options.

Insulin Patches, valued at 1.52 USD billion, represented an innovative approach to insulin delivery, offering enhanced patient comfort and adherence, which is critical in chronic disease management. Meanwhile, Insulin Gels, valued at 1.06 USD billion, while smaller in market size, are gaining traction due to their potential for ease of use and effectiveness.

As the market continues to evolve, advancements in technology and increasing patient awareness about non-invasive methods will drive further expansion. The combined values of these segments underline the varied preferences of patients, with Insulin Pens showing a majority holding in the market, effectively catering to the growing demand for user-friendly insulin delivery systems.

Each product type serves as an opportunity for manufacturers to innovate and meet the needs of a diverse diabetic population, with positions in growth potential shifting as advancements continue to reshape the landscape of insulin administration.

he overall dynamics of these segments reflect growing healthcare trends focused on improving patient experiences, maintaining medication adherence, and adapting solutions to individual needs, ensuring that non-injection insulin methods remain vital in diabetes management strategies.

The opportunities for market growth lie in the development of next-generation devices and formulations that align with patient lifestyle choices, making the Non-injection Insulin Market a significant area of focus for continued research and investment.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Non-injection Insulin Market Therapeutic Area Insights **

The growth of the market is largely driven by the increasing prevalence of diabetes, with a focus on therapeutic areas such as Type 1 Diabetes, Type 2 Diabetes, and Gestational Diabetes.

Type 1 Diabetes represents a critical segment as it requires continuous management, leading to a strong demand for non-injection insulin methods that enhance convenience for patients. Type 2 Diabetes also holds a significant market share due to its widespread occurrence and the growing emphasis on accessible treatment options.

Gestational Diabetes, while less prevalent, is important as it necessitates careful monitoring and management during pregnancy, creating opportunities for innovative non-injection therapies.

Overall, the market's growth is fueled by rising awareness, technological advancements, and a shift toward patient-friendly administration methods, while challenges include regulatory hurdles and the need for robust clinical data.

The diversification within the Non-injection Insulin Market segmentation allows it to cater effectively to the varied needs of patients across these therapeutic areas, thereby bolstering its long-term viability and revenue potential.

### **Non-injection Insulin Market Distribution Channel Insights**

Distribution channels are primarily categorized into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies, each contributing uniquely to the ecosystem. Hospital Pharmacies are significant as they facilitate immediate access to insulin for patients in critical care, while Retail Pharmacies often dominate for their widespread reach and convenience, allowing consumers direct access to medications.

Moreover, the rise of Online Pharmacies is transforming the market landscape, as they offer enhanced accessibility and convenience, particularly appealing to the tech-savvy population. The increasing prevalence of diabetes and the demand for alternative delivery methods drive the expansion of these channels.

Additionally, market growth is supported by technological advancements and a focus on patient-centered care. However, challenges such as regulatory hurdles and the need for better supply chain management remain pivotal.

Overall, the interplay of these distribution channels significantly enhances the Non-injection Insulin Market revenue, underscoring its diverse yet interconnected nature in meeting patient needs.

### **Non-injection Insulin Market End User Insights**

The Non-injection Insulin Market revenue is influenced significantly by its End User segment, which encompasses various settings where this treatment is utilized, including hospitals, home care settings, and diabetes clinics.

Hospitals represent a critical point of care, providing a wide range of diabetes management solutions, while home care settings demonstrate the trend of increased patient self-management and lifestyle convenience.

Diabetes clinics, focused specifically on diabetes care, play a vital role in educating patients about non-injection therapy, ensuring adherence, and ultimately improving health outcomes. The increasing prevalence of diabetes worldwide is a prime growth driver, as is the advancement of technology and delivery systems for insulin therapies.

Each setting addresses unique patient needs and complications, underscoring the diversity of the Non-injection Insulin Market segmentation. With these components in mind, the market is expected to experience a steady growth trajectory backed by increased awareness and a shift toward patient-centric care models.

### **Non-injection Insulin Market Regional Insights**

In 2023, the Non-injection Insulin Market revenue is valued at 7.61 USD billion, with North America representing a significant portion at 3.1 USD billion, marking it as the dominant region in this market. This sub-segment is anticipated to maintain its leadership, projected to reach 5.3 USD billion by 2032, driven by advanced healthcare infrastructure and growing diabetes prevalence.

Europe followed, contributing 2.2 USD billion in 2023 and expected to climb to 3.5 USD billion, benefiting from strong research and development initiatives. The APAC region held a value of 1.6 USD billion in 2023, showing remarkable potential for growth to 2.7 USD billion, attributed to increasing awareness regarding non-injection therapies.

Meanwhile, South America and MEA contributed 0.8 USD billion and 0.71 USD billion respectively, with projections of 1.3 USD billion for South America and 1.2 USD billion for MEA by 2032, indicating a slowly growing market where challenges such as access to healthcare services remain.

The overall Non-injection Insulin Market segmentation reflects diverse regional dynamics, highlighting growth opportunities in less dominant markets. Overall, these market statistics underscore the shifting landscape and the increasing accessibility of non-injection insulin therapies across various regions.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Non-injection Insulin Market Key Players and Competitive Insights**

The Non-injection Insulin Market is characterized by a dynamic landscape where key players are continuously striving to innovate and capture market share amidst growing competition. This market segment has gained traction due to the increasing prevalence of diabetes, which has forced manufacturers to develop more user-friendly and less invasive insulin delivery methods.

The competitive ecosystem is shaped by various factors, including technological advancements, regulatory challenges, and evolving consumer preferences.

As the demand for effective diabetes management solutions escalates, companies in this sector are focusing on research and development to create products that not only meet clinical requirements but also enhance patient adherence and satisfaction through improved delivery methods.

Kanye West's Donda has established a notable presence in the Non-injection Insulin Market by leveraging its strengths in innovation and branding.

The company has effectively utilized its unique position to introduce groundbreaking non-injection [insulin delivery devices](../../../reports/insulin-delivery-devices-market-851) that resonate with the needs of patients. Donda's emphasis on aesthetic design combined with functionality has set it apart from traditional competitors, allowing it to attract a diverse consumer base.

Moreover, the company's commitment to community engagement and educational initiatives has further solidified its standing in the market. This strategic approach to brand loyalty and advocacy not only enhances customer relationships but also positions Donda favorably against competitors, making it a formidable player within the non-injection insulin sector.

Sanofi is a leading entity in the Non-injection Insulin Market, recognized for its comprehensive portfolio of diabetes-related products and solutions. The company possesses significant strengths attributable to its robust research capabilities and established reputation in the pharmaceutical realm. Sanofi has invested extensively in developing advanced non-injection delivery systems that are tailored to meet the specific needs of patients, which has driven high levels of trust and reliability among consumers.

Furthermore, Sanofi's global footprint enables it to effectively navigate diverse regulatory environments and market conditions, allowing the company to maintain a competitive edge. The ongoing commitment to innovation, along with strategic partnerships and alliances, has empowered Sanofi to explore new opportunities and continuously enhance its product offerings, solidifying its leadership position in the market.

### **Key Companies in the non-injection insulin market Include**

## **Non-injection Insulin Market Developments**

Recent developments in the Non-injection Insulin Market highlight significant advancements and strategic movements among key companies. Novo Nordisk, a leading player, has been focusing on the innovation of non-injection delivery mechanisms, enhancing patient adherence and lifestyle integration.

Sanofi and Lilly are also poised to expand their portfolios in oral insulin formulations, responding to the growing demand for user-friendly diabetes management solutions.

The recent partnership between MannKind Corporation and a major pharmaceutical company aims to accelerate the development of inhaled insulin products, showcasing a collaborative effort towards innovative treatments. On the acquisition front, GSK has shown interest in acquiring technologies related to non-injection insulin to diversify its diabetes care offerings.

Market valuations for companies like AstraZeneca and Merck have been positively impacted by their investments in research and development of non-injection delivery systems, signaling a promising growth trajectory.

Additionally, the Diabetes Research Institute continues to lead initiatives focused on improving diabetes management through technological advancements. The momentum in this market indicates a strong commitment from providers to enhance patient experiences while providing effective insulin delivery alternatives.

## **Non-injection Insulin Market Segmentation Insights**

### **Non-injection Insulin Market Product Type Outlook**

- Insulin Patches
- Insulin Inhalers
- Insulin Pens
- Insulin Gels

### **Non-injection Insulin Market Therapeutic Area Outlook**

- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes

### **Non-injection Insulin Market Distribution Channel Outlook**

- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies

### **Non-injection Insulin Market End User Outlook**

- Hospitals
- Home Care Settings
- Diabetes Clinics

### **Non-injection Insulin Market Regional Outlook**

- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa

## Market Drivers

### Rising Prevalence of Diabetes

全球糖尿病的日益普遍是非注射胰岛素市场的主要驱动因素。根据最近的估计，到2045年，糖尿病患者的数量预计将达到7亿。这一糖尿病病例的激增需要开发和提供替代的胰岛素输送方法，例如非注射选项。随着患者寻求更方便和更少侵入性的治疗替代方案，非注射胰岛素制剂的需求可能会增加。这一趋势得到了对糖尿病管理和维持最佳血糖水平重要性日益关注的进一步支持。因此，非注射胰岛素市场预计将显著扩大，以满足这一日益增长的患者群体的需求。

### Government Initiatives and Support

政府在糖尿病管理方面的倡议和支持在非注射胰岛素市场的扩展中发挥着至关重要的作用。各种健康组织和监管机构正在实施旨在改善糖尿病护理和治疗选择的政策。例如，糖尿病药物的补贴和对创新胰岛素输送方法研究的资金支持变得越来越普遍。这些倡议不仅提高了非注射胰岛素产品的可用性，还鼓励制药公司投资于研究和开发。随着政府优先考虑糖尿病管理，非注射胰岛素市场可能会受益于增加的资金和资源，促进创新和可及性。

### Increasing Focus on Patient Compliance

日益关注患者依从性是非注射胰岛素市场的重要驱动因素。非注射胰岛素选项被认为对患者更方便且不那么令人畏惧，这可能会导致治疗方案的依从性改善。研究表明，不遵从注射胰岛素可能导致血糖控制不良和医疗成本增加。通过提供非注射替代方案，医疗提供者旨在增强患者的参与感和满意度。这种以患者为中心的方法的转变可能会刺激对非注射胰岛素产品的需求，因为患者更倾向于遵循与其生活方式偏好相符的治疗计划。因此，非注射胰岛素市场预计将因对依从性的重视而增长。

### Growing Awareness of Diabetes Management

患者和医疗专业人员对糖尿病管理的日益关注正在显著影响非注射胰岛素市场。旨在促进有效糖尿病管理策略的教育活动和资源变得越来越普遍。随着患者对其治疗选择的了解加深，非注射胰岛素替代方案的明显转变正在发生，这些替代方案通常被认为是更少侵入性和更易于使用的。这种提高的意识可能会推动对非注射胰岛素产品的需求，因为患者寻求优化其治疗方案。此外，医疗提供者越来越多地倡导这些替代方案，认识到它们改善患者结果的潜力。因此，非注射胰岛素市场预计将在意识不断提高的情况下经历增长。

### Technological Advancements in Drug Delivery Systems

药物输送系统的技术进步正在推动非注射胰岛素市场向前发展。可吸入胰岛素和口服制剂等创新正在获得关注，为患者提供更友好的选择。例如，可吸入胰岛素在临床试验中显示出良好的结果，证明其与传统注射胰岛素的疗效相当。与移动应用程序连接的智能技术的整合，例如[胰岛素输送设备](https://www.marketresearchfuture.com/reports/insulin-delivery-devices-market-851)，也在增强患者的依从性和监测。这些进步不仅改善了整体患者体验，还促进了非注射胰岛素细分市场的增长。随着技术的不断发展，非注射胰岛素市场可能会见证进一步的创新，以满足糖尿病患者的多样化需求。

## Future Outlook

非注射胰岛素市场预计将在2024年至2035年间以5.67%的年均增长率增长，推动因素包括技术进步、糖尿病患病率上升以及患者对非侵入性选择的偏好。

**New opportunities:**

- 开发口服胰岛素制剂以提高患者依从性。

到2035年，非注射胰岛素市场预计将实现显著增长和创新。

## Segment Insights

### 按应用：2型糖尿病（最大）与1型糖尿病（增长最快）

非注射胰岛素市场展示了一个迷人的应用分布，其中2型糖尿病占据了最大的份额。由于生活方式相关糖尿病的日益普遍，这一细分市场已成为制造商的主要关注点。相比之下，1型糖尿病虽然规模较小，但由于糖尿病管理技术的进步以及患者和医疗专业人员对非注射替代品的认识提高，正在迅速增长。

2型糖尿病（主导）与1型糖尿病（新兴）

2型糖尿病在非注射胰岛素市场中代表了一个主导应用，特点是患者基础更广泛，以及对肥胖和久坐生活方式的日益关注，这些因素导致其发生率增加。该细分市场的治疗集中在口服药物和非注射胰岛素上，提高了患者的依从性和便利性。相反，1型糖尿病由于医疗技术的重大进步而正在崛起，包括吸入胰岛素疗法和创新的给药方法，这些方法正被患者越来越多地采用。围绕新治疗模式的认识提高以及有利于非侵入性解决方案的医疗政策变化，促进了其快速增长。

### 按制剂类型：口服片剂（最大）与吸入胰岛素（增长最快）

在非注射胰岛素市场中，口服片剂占据了最大的市场份额，因其易于使用和消费者熟悉而受到患者的青睐。吸入胰岛素在寻找传统给药方法替代品的用户中迅速获得关注，因此定位为增长最快的制剂。其他细分市场如舌下胰岛素和透皮贴片为整体选择的多样性做出了贡献，但目前在市场中占据的份额较小。

口服片剂（主导）与吸入胰岛素（新兴）

口服片剂因其便利性和患者依从性而受到青睐，使其成为市场中的主导参与者。其已建立的市场地位很好地满足了偏好传统药物形式的患者。相反，吸入胰岛素是一个新兴细分市场，提供了一种新颖的给药方法，由于其非侵入性特征和快速吸收特性，吸引了消费者的兴趣。随着技术的进步，患者教育将推动对吸入选项的接受，从而将这一制剂战略性地定位为糖尿病管理中的下一代解决方案。

### 按分销渠道：零售药店（最大）与在线药店（增长最快）

在非注射胰岛素市场中，分销格局由多种渠道组成，包括医院药房、零售药店、在线药店和专业药店。在这些渠道中，零售药店占据了最大的市场份额，因其广泛的存在和为管理糖尿病患者提供的便利性。相反，在线药店正在迅速崛起，利用电子商务的增长和对家庭配送服务的日益偏好。

零售药店（主导）与在线药店（新兴）

零售药店在非注射胰岛素的分销渠道中占主导地位，因其已建立的基础设施和直接与患者的互动，使患者能够立即获得药物和咨询服务。个性化客户服务和现场健康咨询等特点增强了患者的信任。相反，在线药店代表了一个新兴力量，吸引了寻求便利的技术精明的消费者，且通常提供更好的定价。其增长受到互联网渗透率提高、向数字医疗解决方案转变以及消费者行为变化的推动，偏向于远程购买选项。这一动态正在重塑竞争格局，促使传统参与者进行调整。

### 按患者人口统计：成人患者（最大）与儿童患者（增长最快）

在非注射胰岛素市场的各种患者人口统计中，成人患者占据了最大的细分市场。该群体主要受到2型糖尿病日益普遍和对非注射胰岛素选择认识提高的驱动。同时，儿童患者代表了增长最快的细分市场，受到儿童糖尿病诊断显著增加和对有效管理其病情的日益关注的推动。随着医疗利益相关者认识到需要适合年龄的解决方案，儿童患者可能会看到持续的投资和资源分配。
这些人口统计中的增长趋势受到最近非注射胰岛素制剂进展的显著影响。对于成人患者来说，胰岛素输送的一致性和便利性至关重要，因为他们寻求维持生活质量。相反，儿童患者受益于创新的、用户友好的给药机制，满足他们独特的需求和生活方式。因此，两个细分市场预计将在增强患者参与和遵循治疗方案的市场策略方面经历动态演变。

成人患者（主导）与儿童患者（新兴）

成人患者代表了非注射胰岛素市场中的主导力量，因为该人群中2型糖尿病的高发病率。该群体的特点是对便利的胰岛素输送系统的强烈需求，以适应他们的积极生活方式。另一方面，儿童患者被视为该市场中的新兴细分市场，受到年轻人群中糖尿病发生率增加和对安全、有效的非注射选择需求上升的推动。该细分市场通常需要考虑剂量精确性、口味和使用方便性的特定制剂。两个人口统计对促进创新至关重要，因为它们寻求增强对糖尿病管理的控制，并最终改善患者的生活质量。

### 按治疗用途：血糖控制（最大）与体重管理（增长最快）

在非注射胰岛素市场中，治疗细分市场强调血糖控制作为最大的贡献者，由于其在糖尿病患者中的广泛接受，拥有显著的市场份额。紧随其后，体重管理作为一个值得注意的细分市场出现，迎合了糖尿病患者对肥胖控制的日益关注，尽管在整体市场份额方面仍在追赶。

血糖控制（主导）与体重管理（新兴）

血糖控制在非注射胰岛素市场中代表了一个成熟的细分市场，因其在糖尿病管理中的关键作用而具有高需求。该细分市场主要受到对一致性血糖控制的必要性驱动，定位为糖尿病治疗的基础组成部分。另一方面，体重管理作为一个新兴细分市场，反映了消费者对整体健康方法的日益关注和需求，特别是对于希望在控制血糖水平的同时管理体重的患者。这一趋势表明，关注综合治疗解决方案的转变，旨在同时解决多个健康问题。

## Regional Market Share Analysis

### 北美：创新市场的领导者

北美有望在非注射胰岛素市场中保持其领导地位，预计在2024年占有42.5亿美元的市场份额。该地区的增长受到糖尿病患病率上升、技术进步和支持性监管框架的推动。随着患者寻求更便捷和更少侵入性的治疗方法，对非注射选项的需求正在上升，进一步得到政府倡导糖尿病管理的举措的支持。

北美的竞争格局强劲，主要参与者包括诺和诺德、礼来和赛诺菲。美国作为最大的市场，得益于强大的医疗基础设施和高额的研发投资。公司专注于创新产品开发和战略合作，以增强其市场存在，确保一个动态和竞争的环境。

### 欧洲：具有增长潜力的新兴市场

欧洲的非注射胰岛素市场估值为25亿美元，反映出对创新[糖尿病治疗](https://www.marketresearchfuture.com/reports/diabetes-treatment-market-66483)日益增长的需求。该地区受益于完善的医疗系统和对糖尿病管理意识的提高。监管支持，包括新疗法的简化审批流程，是市场增长的关键驱动因素。向以患者为中心的护理转变也在影响对非注射胰岛素选项的需求，使其成为医疗服务提供者的焦点。

该市场的领先国家包括德国、法国和英国，主要参与者如赛诺菲和勃林格殷格翰积极参与。竞争格局的特点是合作和伙伴关系，旨在增强产品供应。随着市场的发展，公司正在投资研究，以开发更有效和用户友好的胰岛素替代品，使欧洲成为全球市场的重要参与者。

### 亚太地区：快速增长的市场动态

亚太地区的市场规模为17.5亿美元，非注射胰岛素领域正在快速增长。糖尿病患病率上升、医疗支出增加和中产阶级的壮大等因素正在推动需求。监管机构在促进创新疗法方面也发挥着关键作用，预计将增强该地区患者的市场可及性和可负担性。

中国和印度等国正在引领潮流，在医疗基础设施和糖尿病管理项目方面进行重大投资。竞争格局中包括礼来和曼科德公司等主要参与者，他们专注于扩大产品组合。随着该地区的持续发展，对非注射选项的重视可能会重塑治疗范式，使其成为市场增长的关键领域。

### 中东和非洲：具有挑战的新兴市场

中东和非洲（MEA）地区的市场规模为5亿美元，在非注射胰岛素市场中呈现出独特的挑战和机遇。糖尿病发病率上升，加上医疗保健的有限获取，正在推动对创新治疗选择的需求。监管框架正在逐步演变，以支持非注射疗法的引入，这可能会增强患者的获取和依从性。

南非和阿联酋等国在这一市场中处于前沿，医疗基础设施的投资不断增加。然而，竞争格局仍然分散，许多本地和国际参与者争夺市场份额。公司专注于教育和宣传活动，以推广非注射选项，这可能会显著影响该地区患者的结果。

## Competitive Benchmarking

非注射胰岛素市场目前的特点是动态的竞争格局，受到糖尿病患病率上升和对以患者为中心的治疗选择需求增长的推动。诺和诺德（丹麦）、赛诺菲（法国）和礼来公司（美国）等主要参与者在战略上定位，以利用创新并扩大其产品供应。诺和诺德（丹麦）专注于开发口服胰岛素配方，而赛诺菲（法国）则强调合作伙伴关系以增强其市场覆盖。礼来公司（美国）正在投资数字健康解决方案以改善患者依从性，共同塑造一个优先考虑以患者为中心的方法和技术进步的竞争环境。

该市场内的关键商业策略包括本地化制造和优化供应链以提高效率和降低成本。竞争结构似乎适度分散，几家主要参与者对市场动态施加影响。这种分散性允许多样化的策略，使公司能够满足特定地区的需求，同时保持竞争优势。

在2026年1月，诺和诺德（丹麦）宣布与一家领先的技术公司合作，开发旨在改善患者胰岛素管理的数字平台。这一战略举措可能会增强患者参与度和依从性，使诺和诺德（丹麦）成为将技术与糖尿病护理整合的领先者。这一合作强调了数字解决方案在当前市场格局中的重要性。

在2025年12月，赛诺菲（法国）在部分欧洲市场推出了一种新的口服胰岛素产品，标志着其非注射产品组合的重要扩展。这一推出表明赛诺菲致力于满足患者对更便捷治疗选择的需求。这一产品的推出可能会占据相当大的市场份额，反映出对非注射疗法日益增长的趋势。

在2025年11月，礼来公司（美国）与一家远程医疗提供商揭晓了一项合作关系，提供使用其非注射胰岛素产品的患者的远程监测服务。预计这一举措将增强患者支持并改善健康结果，与将医疗服务与技术整合的更广泛趋势相一致。这类合作可能会重新定义市场中的患者参与策略。

截至2026年2月，目前的竞争趋势越来越多地由数字化、可持续性和人工智能（AI）在产品开发和患者管理中的整合所定义。战略联盟在塑造市场格局中发挥着关键作用，使公司能够集中资源和专业知识。展望未来，竞争差异化可能会从传统的基于价格的竞争转向关注创新、技术进步和供应链可靠性，因为公司努力满足患者和医疗服务提供者不断变化的需求。

## Recent News & Developments

非注射胰岛素市场的最新发展突显了主要公司之间的显著进展和战略动向。作为领先参与者的诺和诺德一直专注于非注射输送机制的创新，增强患者依从性和生活方式整合。

赛诺菲和礼来也准备扩大其口服胰岛素配方的产品组合，以应对对用户友好的糖尿病管理解决方案日益增长的需求。

曼科德公司与一家主要制药公司之间的最新合作旨在加速吸入式胰岛素产品的开发，展示了朝着创新治疗的合作努力。在收购方面，GSK对收购与非注射胰岛素相关的技术表现出兴趣，以多样化其糖尿病护理产品。

阿斯利康和默克等公司的市场估值因其在非注射输送系统的研究和开发投资而受到积极影响，显示出良好的增长轨迹。

此外，糖尿病研究所继续领导旨在通过技术进步改善糖尿病管理的倡议。该市场的势头表明，提供者在提升患者体验的同时，致力于提供有效的胰岛素输送替代方案。

## Report Scope

| 市场规模 2024 | 85(十亿美元) |
| --- | --- |
| 市场规模 2025 | 89.8(十亿美元) |
| 市场规模 2035 | 155.9(十亿美元) |
| 复合年增长率 (CAGR) | 5.67% (2024 - 2035) |
| 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 |
| 基准年 | 2024 |
| 市场预测期 | 2025 - 2035 |
| 历史数据 | 2019 - 2024 |
| 市场预测单位 | 十亿美元 |
| 主要公司简介 | 诺和诺德 (丹麦)、赛诺菲 (法国)、勃林格殷格翰 (德国)、百时美施贵宝 (美国)、曼金德公司 (美国)、礼来公司 (美国)、阿斯利康 (英国)、辉瑞 (美国)、罗氏 (瑞士) |
| 覆盖的细分市场 | 应用、配方类型、分销渠道、患者人口统计、治疗用途 |
| 主要市场机会 | 口服给药系统的进步提高了非注射胰岛素市场的患者依从性。 |
| 主要市场动态 | 消费者对非注射胰岛素选择的偏好上升，推动了制药公司的创新和竞争。 |
| 覆盖的国家 | 北美、欧洲、亚太、南美、中东和非洲 |

## Frequently Asked Questions

**Q: 非注射胰岛素市场目前的估值是多少？**
A: 非注射胰岛素市场在2024年的估值为85亿美元。

**Q: 到2035年，非注射胰岛素市场的预计市场规模是多少？**
A: 预计到2035年，市场将达到155.9亿美元。

**Q: 在预测期内，非注射胰岛素市场的预期年均增长率是多少？**
A: 预计非注射胰岛素市场在2025年至2035年间的年均增长率为5.67%。

**Q: 哪些公司是非注射胰岛素市场的关键参与者？**
A: 关键参与者包括诺和诺德、赛诺菲、勃林格殷格翰和礼来等。

**Q: 2型糖尿病市场细分与其他应用相比如何？**
A: 2型糖尿病细分预计将从40亿美元增长到70亿美元，表明需求强劲。

**Q: 在非注射胰岛素市场中，口服片的预计收入是多少？**
A: 预计口服片在2035年前将产生25.5亿到45.5亿美元的收入。

**Q: 在非注射胰岛素市场中，预计哪个分销渠道的收入最高？**
A: 零售药店预计将从32亿美元增长到58亿美元，表明其领先地位。

**Q: 到2035年，吸入胰岛素的预计收入增长是多少？**
A: 预计吸入胰岛素将从20亿美元增长到35亿美元。

**Q: 在收入方面，儿童患者市场与成人患者市场相比如何？**
A: 儿童患者细分预计将从15亿美元增长到27亿美元，而成人患者可能在2035年达到40亿到70亿美元。

**Q: 预计在非注射胰岛素市场中，哪个治疗用途将产生最高收入？**
A: 血糖控制预计将从34亿美元增长到61亿美元，表明其在市场中的关键作用。


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/non-injectable-insulin-market-35002*
